NEW YORK (TheStreet) --BG Medicine (BGMD) was rising 26.97% to $1.46 on Tuesday after the diagnostics company published results of a clinical research study that validated the performance of the VIDAS Galectin-3, an automated assay developed by bioMerieux. <\/p>\n
The results, which were posted online prior to its print publication in the journalClinica Chimica Acta, noted that elevated galectin-3 levels in blood samples that had been previously collected and then measured with the VIDAS Galectin-3 assay largely predicted fatal cardiovascular events. The assay also significantly predicted the severity of heart failure in the 137 tested patients, all of whom had been diagnosed with chronic heart failure. <\/p>\n
TheStreet Ratings team rates BG MEDICINE INC as a \"sell\" with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation: <\/p>\n
\"We rate BG MEDICINE INC (BGMD) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk.\" <\/p>\n
<\/p>\n
See original here:<\/p>\n
Why BG Medicine (BGMD) Is Up Today<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK (TheStreet) --BG Medicine (BGMD) was rising 26.97% to $1.46 on Tuesday after the diagnostics company published results of a clinical research study that validated the performance of the VIDAS Galectin-3, an automated assay developed by bioMerieux. Continue reading